Guardant Health – $273.1 Million IPO

Cooley advised the underwriters on Guardant Health, Inc.’s $273.1 million initial public offering of 14,375,000 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares. Partners Charlie Kim, Dave Peinsipp and Drew Williamson led the Cooley team advising the underwriters.

J.P. Morgan Securities and Bank of America Merrill Lynch acted as joint book-running managers for the offering. Cowen and Company, Leerink Partners and William Blair & Company acted as co-managers for the offering.

Guardant is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The company’s shares now trade on the Nasdaq Global Market under the symbol “GH.”

Related Contacts
Charlie Kim Partner, San Diego
David Peinsipp Partner, San Francisco
Drew Williamson Partner, San Francisco
Kristin VanderPas Partner, San Francisco
Denny Won Associate, San Francisco
Christopher Wong Associate, San Francisco
Related Practices & Industries

Capital Markets Public Companies Life Sciences